The Effect of Oral Oxytocin and Atosiban on Top-down Attention ( OTAtosiban )

NCT07140237 | Recruiting Early Phase 1

• 1 other identifier: UESTC-neuSCAN99
• Study Type: interventional
• Target: 250
• Locations: 1 country
• Sites: 1

Brief Summary

The main aim of the present study is to investigate whether orally (lingual spray) administered oxytocin influences human top-down attention via oxytocin receptors and whether its effects are dose- and task-dependent.

Conditions

Healthy Adult Male

Keywords

Oxytocin; Atosiban; Eye-tracking; Autistic trait; Oxytocin; Atosiban; Eye-tracking; Autistic trait; attention

Outcome Measures

Primary Outcomes (2)

• Error rates in prosaccade and antisaccade trials

  Error rates in prosaccade and antisaccade using eye- tracking technique

  Starting 45 minutes post-treatment subjects will complete the eye-tracking task with data on numbers of prosaccade and antisaccade errors being collected continuously over a period of 35 minutes.

• Responses latencies for prosaccades and antisaccades

  response latencies for correct first saccades will be measured on each prosaccade or antisaccade trial using eye-tracking

  Starting 45 minutes post-treatment subjects will complete the eye-tracking task with data on prosaccade and antisaccade response times taken continuously during the 35 minute task

Secondary Outcomes (4)

• Oxytocin concentration

  On the day of the experiment blood and saliva samples will be taken at time 0 (baseline) immediately prior to the first treatment, a 2nd sample will be taken at 15 minutes and a 3rd sample at 45 minutes post-treatment.

• Pupil size

  Starting 45 minutes post-treatment continuous eye-tracking will be used to measure changes in pupil size during the whole of the 35 minute antisaccade task

• State anxiety

  On the day of the experiment subjects will complete the questionnaire immediately prior to treatment at time 0 (baseline) and again 75 minutes post-treatment after completion of the antisaccade task

• Correlation between prosaccade latency and antisaccade errors

  Starting 45 minutes post-treatment subjects will complete the eye-tracking task with data being collected continuously over a 35 minute period

Study Arms (5)

Oxtocin 24IU group

EXPERIMENTAL

Interventions are placebo followed after 15 minutes by the lower does (24IU) oxytocin

Drug: Oxytocin lower does (24IU); Drug: Placebo

atosiban group

EXPERIMENTAL

Interventions are placebo followed after 15 minutes by 150ug atosiban

Drug: Atosiban; Drug: Placebo

placebo group

PLACEBO COMPARATOR

Interventions are placebo followed after 15 minutes by another placebo

Drug: Placebo

Oxytocin 48IU group

EXPERIMENTAL

Interventions are placebo followed after 15 minutes by the higher 48IU oxytocin does

Drug: Oxytocin higher does (48IU); Drug: Placebo

Atosiban and 24IU oxytocin group

EXPERIMENTAL

Interventions are atosiban 150ug followed after 15 minutes by the lower (24IU) does of oxytocin

Drug: Oxytocin lower does (24IU); Drug: Atosiban

Interventions

Oxytocin lower does (24IU) DRUG

Oxytocin (24IU) will be administered as a lingual spray (6, 0.1puffs (4IU per puff) of spray on and under the tongue)

Atosiban and 24IU oxytocin group; Oxtocin 24IU group

Oxytocin higher does (48IU) DRUG

Oxytocin (48IU) will be administered as a lingual spray (6, 0.1ml sprays (8IU per puff) on and under the tongue)

Oxytocin 48IU group

Atosiban DRUG

150ug atosiban administered by lingual sprays (6, 0.1ml sprays on and under the tongue)

Atosiban and 24IU oxytocin group; atosiban group

Placebo DRUG

Placebo administered as a lingual spray (6, 0.1puffs (4IU per puff) of spray on and under the tongue). Placebo has the same composition of 0.9% saline and glycerol as for oxytocin and the atosiban interventions.

Oxtocin 24IU group; Oxytocin 48IU group; atosiban group; placebo group

Eligibility Criteria

• Age: 18 Years - 35 Years
• Gender Eligibility Details: Healthy male subjects without past or current psychiatric or neurological disorders
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Healthy male subjects without past or current psychiatric or neurological disorders

You may not qualify if:

• History of or current neurological/psychiatric disorders;
• Use of psychotropic medications (including nicotine)
• Visual impairments

Sponsors & Collaborators

• University of Electronic Science and Technology of China: lead

Study Sites (1)

School of Life science and Technology, University of Electronic Science and Technology of China

Chengdu, Sichuan, China

RECRUITING

MeSH Terms

Interventions

atosiban

Central Study Contacts

Keith M Kendrick, PhD

CONTACT

+86-28-61830811; k.kendrick.uestc@gmail.com

Yige Wang, PhD

CONTACT

+86-13086688860

Study Design

• Study Type: interventional
• Phase: early phase 1
• Allocation: NON RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: BASIC SCIENCE
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor

Model Details: Randomized placebo-controlled double-blind between-subject design experiment including 5 treatment groups receiving oral oxytocin, atosiban, or placebo interventions prior to performing antisaccade task.

Study Record Dates

• First Submitted: August 18, 2025
• First Posted: August 24, 2025
• Study Start: September 1, 2025
• Primary Completion: December 30, 2025
• Study Completion: December 30, 2025
• Last Updated: September 8, 2025

Record last verified: 2025-09

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)